PT - JOURNAL ARTICLE AU - Qin, Rui AU - Kurz, Emma AU - Chen, Shuhui AU - Zeck, Briana AU - Chiribogas, Luis AU - Jackson, Dana AU - Herchen, Alex AU - Attia, Tyson AU - Carlock, Michael AU - Rapkiewicz, Amy AU - Bar-Sagi, Dafna AU - Ritchie, Bruce AU - Ross, Ted M. AU - Mahal, Lara K. TI - α2,6-Sialylation is Upregulated in Severe COVID-19 Implicating the Complement Cascade AID - 10.1101/2022.06.06.22275981 DP - 2022 Jan 01 TA - medRxiv PG - 2022.06.06.22275981 4099 - http://medrxiv.org/content/early/2022/06/08/2022.06.06.22275981.short 4100 - http://medrxiv.org/content/early/2022/06/08/2022.06.06.22275981.full AB - Better understanding of the mechanisms of COVID-19 severity is desperately needed in current times. Although hyper-inflammation drives severe COVID-19, precise mechanisms triggering this cascade and what role glycosylation might play therein is unknown. Here we report the first high-throughput glycomic analysis of COVID-19 plasma samples and autopsy tissues. We find α2,6-sialylation is upregulated in plasma of patients with severe COVID-19 and in the lung. This glycan motif is enriched on members of the complement cascade, which show higher levels of sialylation in severe COVID-19. In the lung tissue, we observe increased complement deposition, associated with elevated α2,6-sialylation levels, corresponding to elevated markers of poor prognosis (IL-6) and fibrotic response. We also observe upregulation of the α2,6-sialylation enzyme ST6GAL1 in patients who succumbed to COVID-19. Our work identifies a heretofore undescribed relationship between sialylation and complement in severe COVID-19, potentially informing future therapeutic development.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe NYULH Center for Biospecimen Research and Development, Histology and Immunohistochemistry Laboratory (RRID:SCR_018304), is supported in part by the Laura and Isaac Perlmutter Cancer Center Support Grant (NIH/NCI P30CA016087). This project has been funded by the National Institute of Allergy and Infectious Diseases, a component of the NIH, Department of Health and Human Services, under contract 75N93019C00052 (T.M.R and L.K.M.) and the Canada Excellence Research Chair Program (L.K.M.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research Ethics Board of the University of Alberta gave ethical approval for this work (COVID-19 plasma) Ethics Committee/IRB of the University of Georgia gave ethical approval for this work (control plasma). Ethics Commitee/IRB of NYU Winthrop gave ethical approval for this work (COVID and control tissue samples)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesLectin microarray data for plasma samples and autopsy samples are available at Synapse.org (doi: 10.7303/syn27791795). All other data produced in the present work are contained in the manuscript https://doi.org/10.7303/syn27791795